Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
LH submitted a Form 144 notice reporting an insider sale and recent vested issuances. The filing shows 548 shares sold on 02/27/2026 for $155,999.54. The report lists multiple restricted stock vesting events (examples: 03/26/2026 3,659 shares; 03/27/2025 1,973 shares) and an ESPP purchase on 06/30/2025.
Labcorp Holdings Inc. reported first-quarter 2026 revenues of $3,537.6 million, up 5.8% from 2025, driven by 3.1% organic growth, acquisitions, and favorable currency. Diagnostics Laboratories contributed $2,762.1 million (5.0% growth) and Biopharma Laboratory Services $780.6 million (8.2% growth).
Net earnings attributable to Labcorp rose to $277.8 million from $212.8 million, with diluted EPS increasing to $3.35 from $2.52. Cost of revenues fell slightly as a percentage of sales and SG&A leveraged on higher revenue, supporting operating income of $380.8 million.
Operating cash flow improved sharply to $191.5 million. The company spent $202.2 million on acquisitions, including Empire City Laboratories, and repurchased 0.4 million shares for $98.0 million. It ended the quarter with $981.1 million in cash, a new $750.0 million term loan, ongoing share repurchase authorization, and a quarterly dividend of $0.72 per share.
Labcorp Holdings reported solid growth for the first quarter ended March 31, 2026 and raised its full‑year 2026 outlook. Revenue reached $3.54 billion, up 5.8% from $3.35 billion a year ago, driven by both Diagnostics Laboratories and Biopharma Laboratory Services.
Diluted EPS rose to $3.35 from $2.52, while Adjusted EPS increased 10.6% to $4.25. Operating income improved to $380.8 million and adjusted operating margin expanded to 14.4% from 14.0%. Free cash flow swung to $70.5 million from negative $107.5 million, helped by higher cash earnings.
Diagnostics revenue grew 5.0% to $2.76 billion with adjusted margin of 16.6%, and Biopharma revenue grew 8.2% to $780.6 million with a 15.5% adjusted margin. Labcorp invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid $61.2 million in dividends.
For 2026, the company now targets enterprise revenue of $14.65–$14.80 billion (5.0–6.1% growth) and Adjusted EPS of $17.70–$18.35, modestly above its prior ranges.
Vanguard Capital Management reports beneficial ownership of 6,201,512 shares of Labcorp Holdings Inc common stock, representing 7.52% of the class as of 03/31/2026. The filing shows sole voting power of 825,392 shares and sole dispositive power over 6,201,512 shares. The Schedule 13G is signed on 04/28/2026 by Ashley Grim.
Labcorp Holdings Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on May 21, 2026 to elect eleven directors, approve executive pay on an advisory basis, and ratify Deloitte & Touche LLP as auditor for 2026.
For 2025, Labcorp reports revenues of $14.0 billion versus $13.0 billion last year, diluted EPS of $10.46 versus $8.84, adjusted EPS of $16.44 versus $14.57, and free cash flow of $1.2 billion versus $1.1 billion. Management highlights 13 transactions with health systems and labs, more than 130 new tests launched in high‑growth areas, and technology and AI tools to support diagnostics and clinical trials.
The proxy emphasizes board refreshment, with ten of eleven nominees independent and 64% overall diversity, strong shareholder engagement with meetings representing over 80% of shares, and a pay‑for‑performance philosophy where about 76% of the CEO’s 2025 target compensation and 69% for other named executives are performance‑based and at risk.
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on June 11, 2026 to stockholders who are on record at the close of business on May 29, 2026.
The company highlights its global scale, noting nearly 71,000 employees serving clients in about 100 countries and performing more than 750 million tests annually, as well as providing support for 85% of new drugs and therapeutic products approved by the FDA in 2025.
Labcorp Holdings Inc. will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026, and will host a conference call and webcast at 9:00 a.m. ET to discuss the results.
The earnings press release and financial information will be posted on the Labcorp Investor Relations website, where a link to the webcast and a replay available for one year will also be provided. Labcorp is described as a global leader in laboratory services, with nearly 71,000 employees serving clients in about 100 countries.
LABCORP HOLDINGS INC. President & CEO Adam H. Schechter received a grant of 58,470 shares of Common Stock on March 26, 2026, as a performance award tied to results for the three-year period ended December 31, 2025. To cover related tax obligations, 26,106 shares of Common Stock were withheld at $268.38 per share rather than sold in the open market. After these compensation and tax-withholding entries, Schechter directly holds 113,137 shares of Common Stock.
LABCORP HOLDINGS INC. executive Anita Z. Graham, EVP and CHRO, received 6,604 shares of common stock on March 26, 2026 as a performance-based equity award. The award relates to performance over the three-year period ended December 31, 2025 from a grant made on April 5, 2023.
To cover tax withholding obligations, 2,879 shares were automatically withheld at $268.38 per share, which is recorded as a disposition but is not an open-market sale. After these transactions, Graham directly holds 5,185 shares of Labcorp common stock.